Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
14 studies found for:    TBR-652
Show Display Options
Rank Status Study
1 Completed Effect of Cenicriviroc on HIV Neurocognitive Impairment
Conditions: AIDS Dementia Complex;   HIV-1-Associated Cognitive Motor Complex;   Human Immunodeficiency Virus
Intervention: Drug: cenicriviroc
2 Enrolling by invitation Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis
Conditions: Nonalcoholic Steatohepatitis;   Liver Cirrhosis;   Non-alcoholic Fatty Liver Disease
Intervention: Drug: Cenicriviroc
3 Completed A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients
Condition: HIV-1 Infection
Interventions: Drug: TBR-652;   Drug: TBR-652 Matching Placebo;   Drug: TBR-652 50 mg;   Drug: TBR-652 75 mg;   Drug: TBR-652 100 mg;   Drug: TBR-652 150 mg
4 Completed Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam
Condition: HIV-infection/AIDS
Interventions: Drug: Cenicriviroc;   Drug: Dolutegravir;   Drug: Midazolam
5 Completed Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment
Condition: Liver Insufficiency
Interventions: Drug: Cenicriviroc in mild liver impaired;   Drug: Cenicriviroc in moderate liver impaired
6 Active, not recruiting Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Subjects With Liver Fibrosis
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: Cenicriviroc;   Drug: Placebo
7 Recruiting PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis
Condition: Primary Sclerosing Cholangitis
Intervention: Drug: Cenicriviroc 150 mg
8 Terminated Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors
Condition: HIV Infection
Intervention:
9 Completed Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination
Condition: Healthy
Interventions: Drug: Cenicriviroc;   Drug: Pioglitazone
10 Completed Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Condition: HIV-1 Infection
Interventions: Drug: Cenicriviroc 100 mg;   Drug: Cenicriviroc 200 mg + Truvada;   Drug: Sustiva + Truvada
11 Recruiting AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: Cenicriviroc;   Drug: Placebo
12 Active, not recruiting Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
Condition: Healthy
Interventions: Drug: Cenicriviroc;   Drug: Omeprazole;   Drug: Famotidine
13 Active, not recruiting ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD
Conditions: Prediabetic State;   Non-alcoholic Fatty Liver Disease;   Type 2 Diabetes Mellitus
Interventions: Drug: Cenicriviroc 150 mg;   Drug: Matching placebo
14 Active, not recruiting Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin
Condition: Healthy
Interventions: Drug: Rosuvastatin;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Digoxin;   Drug: Caffeine

Study has passed its completion date and status has not been verified in more than two years.